Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
出版年份 2018 全文链接
标题
Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers
作者
关键词
-
出版物
Frontiers in Oncology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-11-28
DOI
10.3389/fonc.2018.00563
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists
- (2018) Mauro Frigeri et al. CANADIAN JOURNAL OF CARDIOLOGY
- Gut microbiome modulates efficacy of immune checkpoint inhibitors
- (2018) Ming Yi et al. Journal of Hematology & Oncology
- Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
- (2018) Javid J Moslehi et al. LANCET
- A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo
- (2018) Suping Li et al. NATURE BIOTECHNOLOGY
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma
- (2018) W-W Deng et al. ORAL DISEASES
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
- (2018) Chao Wang et al. Science Translational Medicine
- Gavage of Fecal Samples From Patients With Colorectal Cancer Promotes Intestinal Carcinogenesis in Germ-Free and Conventional Mice
- (2017) Sunny H. Wong et al. GASTROENTEROLOGY
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- (2017) Joshua Bauml et al. JOURNAL OF CLINICAL ONCOLOGY
- Fatal Myocarditis Following Treatment with the PD-1 Inhibitor Nivolumab
- (2017) Daniel R. Matson et al. JOURNAL OF FORENSIC SCIENCES
- PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
- (2017) Tim Wartewig et al. NATURE
- Cancer immunotherapy: The dark side of PD-1 receptor inhibition
- (2017) Aya Ludin et al. NATURE
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- A STING-activating nanovaccine for cancer immunotherapy
- (2017) Min Luo et al. Nature Nanotechnology
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Immunotherapy in head and neck cancer: Need for a new strategy? Rapid progression with nivolumab then unexpected response with next treatment
- (2017) Amaury Daste et al. ORAL ONCOLOGY
- A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141
- (2017) Naomi Kiyota et al. ORAL ONCOLOGY
- Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development
- (2017) Hua Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models
- (2017) Egle Cekanaviciute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice
- (2017) Kerstin Berer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Autoimmune Cardiotoxicity of Cancer Immunotherapy
- (2017) Feixiong Cheng et al. TRENDS IN IMMUNOLOGY
- TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
- (2017) Florie Bertrand et al. Nature Communications
- Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
- (2017) Zuqiang Liu et al. Nature Communications
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
- (2016) Raghvendra M. Srivastava et al. CLINICAL CANCER RESEARCH
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
- (2016) Laura Q.M. Chow et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
- (2016) Tanguy Y Seiwert et al. LANCET ONCOLOGY
- Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung
- (2016) H. Semper et al. LUNG CANCER
- Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody
- (2016) Chao Wang et al. NANO LETTERS
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Unmasking PD-1 Resistance by Next-Generation Sequencing
- (2016) Carlo B. Bifulco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monitoring and Management of Immune‐Related Adverse Events Associated With Programmed Cell Death Protein‐1 Axis Inhibitors in Lung Cancer
- (2016) Grainne M. O'Kane et al. ONCOLOGIST
- OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment
- (2016) R. Bryan Bell et al. ORAL ONCOLOGY
- Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
- (2016) Paul E. Hughes et al. TRENDS IN IMMUNOLOGY
- Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis
- (2016) Xi Zhang et al. Drug Design Development and Therapy
- CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
- (2016) Guang-Tao Yu et al. OncoImmunology
- Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer
- (2016) Mizuki Nishino et al. JAMA Oncology
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data
- (2015) Mark S. Swanson et al. ORAL ONCOLOGY
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
- (2015) A. Sivan et al. SCIENCE
- Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck
- (2015) Philip Pancari et al. Surgical Oncology Clinics of North America
- Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
- (2015) Cuiping Liu et al. ARTHRITIS RESEARCH & THERAPY
- Pembrolizumab
- (2015) Leila Khoja et al. Journal for ImmunoTherapy of Cancer
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma
- (2015) Heinz Läubli et al. Journal for ImmunoTherapy of Cancer
- Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma
- (2014) Ian-James Malm et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
- (2014) Valerie A. Gerriets et al. JOURNAL OF CLINICAL INVESTIGATION
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Serine-threonine kinases in TCR signaling
- (2014) María N Navarro et al. NATURE IMMUNOLOGY
- Reconstructed Adeno-Associated Virus with the Extracellular Domain of Murine PD-1 Induces Antitumor Immunity
- (2013) Osama A.O. Elhag et al. Asian Pacific Journal of Cancer Prevention
- Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
- (2013) H-B Jie et al. BRITISH JOURNAL OF CANCER
- Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
- (2013) S. Lyford-Pike et al. CANCER RESEARCH
- Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
- (2013) P. A. Ascierto et al. CLINICAL CANCER RESEARCH
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Two DNA nanomachines map pH changes along intersecting endocytic pathways inside the same cell
- (2013) Souvik Modi et al. Nature Nanotechnology
- Oral complications of cancer and cancer therapy
- (2012) Joel B. Epstein et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel targeted therapies in head and neck cancer
- (2012) Mariana B A Ferreira et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis
- (2012) M. L. Tarrio et al. JOURNAL OF IMMUNOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads
- (2012) S. M. Douglas et al. SCIENCE
- Commentary
- (2011) Barbara Burtness CANCER JOURNAL
- Bacterial Magnetosome: A Novel Biogenetic Magnetic Targeted Drug Carrier with Potential Multifunctions
- (2011) Jianbo Sun et al. Journal of Nanomaterials
- T Cell-Tumor Interaction Directs the Development of Immunotherapies in Head and Neck Cancer
- (2010) A. E. Albers et al. Clinical & Developmental Immunology
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
- (2009) Ezra EW Cohen et al. LANCET ONCOLOGY
- OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor
- (2008) M. J. Gough et al. CANCER RESEARCH
- Head and neck cancer
- (2008) Athanassios Argiris et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started